COVID-19疫苗接种对接受靶向治疗的类风湿关节炎和银屑病关节炎患者疾病活动度的影响:COVIDSER研究
COVIDSER研究纳入1765例接种COVID-19疫苗的RA(1178例,66.7%)和PsA(587例,33.3%)患者,分析接种前后DAS28疾病活动度和 flare 率变化。疫苗接种未显著改变疾病活动度分布或flare率,但RA中接受JAK抑制剂和IL-6抑制剂治疗者、PsA中接受IL-12/23抑制剂治疗者疾病活动度较TNF抑制剂治疗者恶化。
要点
- 疫苗接种未显著改变RA和PsA患者总体DAS28疾病活动度分布或flare率。
- RA患者中,JAK抑制剂和IL-6抑制剂治疗者DAS28变化较TNF抑制剂治疗者恶化。
- PsA患者中,IL-12/23抑制剂治疗者DAS28变化较TNF抑制剂治疗者恶化。
核心结论
- COVID-19疫苗接种与RA和PsA患者flare率增加无关,但RA中接受JAK-i和IL-6-i治疗者及PsA中接受IL-12/23-i治疗者疾病活动度可能增加,需进一步研究。
研究设计与样本
- COVIDSER项目纳入1765例接种COVID-19疫苗的RA或PsA患者,其中RA 1178例(66.7%)、PsA 587例(33.3%),收集人口学、疾病特征、DAS28和靶向治疗数据。
- 采用对数线性回归分析基于DAS28的flare率,列联分析比较接种前后疾病活动度分类分布,随机系数模型评估DAS28连续变化。
主要发现
- 疫苗接种未显著改变疾病活动度分类分布和flare率。
- 对数线性回归显示,接种后6个月期间flare率与接种前同期相比,RA和PsA患者均无显著变化。
- 随机系数模型显示,接种后两组患者DAS28变化均无显著差异。
- RA患者中,JAK-i治疗者DAS28变化为1.436±0.531(p=0.007),IL-6-i治疗者为1.201±0.550(p=0.029),均较TNF-i治疗者恶化。
- PsA患者中,IL-12/23-i治疗者DAS28变化为4.476±1.906(p=0.019),较TNF-i治疗者恶化。
关键数值与推荐
- RA患者中,JAK-i治疗者DAS28变化1.436±0.531(p=0.007),IL-6-i治疗者1.201±0.550(p=0.029),均较TNF-i治疗者恶化。
- PsA患者中,IL-12/23-i治疗者DAS28变化4.476±1.906(p=0.019),较TNF-i治疗者恶化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出,RA中接受JAK-i和IL-6-i治疗者及PsA中接受IL-12/23-i治疗者疾病活动度可能增加,需进一步研究(warrants further investigation)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under targeted therapies. PATIENTS AND METHODS: 1765 vaccinated patients COVID-19, 1178 (66.7%) with RA and 587 (33.3%) with PsA from the COVID-19 registry in patients with rheumatic diseases (COVIDSER) project, were included. Demographics, disease characteristics, Disease Activity Score in 28 joints (DAS28) and targeted treatments were collected. DAS28-based flare rates and categorised disease activity distribution prevaccination and post vaccination were analysed by log-linear regression and contingency analyses, respectively. The influence of vaccination on DAS28 variation as a continuous measure was evaluated using a random coefficient model. RESULTS: The distribution of categorised disease activity and flare rates was not significantly modified by vaccination. Log-linear regression showed no significant changes in the rate of flares in the 6-month period after vaccination compared with the same period prior to vaccination in neither patients with RA nor patients with PsA. When DAS28 variations were analysed using random coefficient models, no significant variations in disease activity were detected after vaccination for both groups of patients. However, patients with RA treated with Janus kinase inhibitors (JAK-i) (1) and interleukin-6 inhibitor (IL-6-i) experienced a worsening of disease activity (1.436±0.531, p=0.007, and 1.201±0.550, p=0.029, respectively) in comparison with those treated with tumour necrosis factor inhibitor (TNF-i). Similarly, patients with PsA treated with interleukin-12/23 inhibitor (IL-12/23-i) showed a worsening of disease activity (4.476±1.906, p=0.019) compared with those treated with TNF-i. CONCLUSION: COVID-19 vaccination was not associated with increased rate of flares in patients with RA and PsA. However, a potential increase in disease activity in patients with RA treated with JAK-i and IL-6-i and in patients with PsA treated with IL-12/23-i warrants further investigation.
引用
- Álvaro-Gracia JM, Sanchez-Piedra C, Culqui D, et al. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study. RMD Open. 2023. PMID: 36927849. doi:10.1136/rmdopen-2022-002936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。